75176-20-4

Basic information

• Product Name: N-(benzyloxycarbonyl)-cis-4-methoxy-L-proline
• Synonyms: N-(benzyloxycarbonyl)-cis-4-methoxy-L-proline
• CAS NO: 75176-20-4
• Molecular Weight: 279.293
• Mol File: 75176-20-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-(benzyloxycarbonyl)-cis-4-methoxy-L-proline(CAS DataBase Reference)
• NIST Chemistry Reference: N-(benzyloxycarbonyl)-cis-4-methoxy-L-proline(75176-20-4)
• EPA Substance Registry System: N-(benzyloxycarbonyl)-cis-4-methoxy-L-proline(75176-20-4)

Safety Data

• Hazardous Substances Data: 75176-20-4(Hazardous Substances Data)

Upstream product

• 13504-86-4 (2S,4S)-1-benzyloxycarbonyl-4-hydroxyproline 
• 75176-19-1 N-<(phenylmethoxy)carbonyl>-4(S)-methoxy-(S)-proline methyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 858971-57-0 (2S,4S)-1-benzyloxycarbonyl-4-methoxy-2-pyrrolidinylmethanol 
• 75176-19-1 N-<(phenylmethoxy)carbonyl>-4(S)-methoxy-(S)-proline methyl ester 
• 871979-08-7 3-[2-(1-benzyloxycarbonyl-(4S)-methoxy-(2S)-pyrrolidinyl)-5-oxazolyl]propionic acid methyl ester 
• 871979-10-1 3-[2-[1-[2,5-dichloro-4-(1-methyl-3-indolylcarbonylamino)phenylacetyl]-(4S)-methoxy-(2S)-pyrrolidinyl]-5-oxazolyl]propionic acid methyl ester 
• 871979-07-6 5-[(1-benzyloxycarbonyl-(4S)-methoxy-(2S)-pyrrolidinyl)carbonylamino]levulinic acid methyl ester 
• 113949-62-5 (2S,4S)-1-{2-[Hydroxy-(4-phenyl-butyl)-phosphinoyl]-acetyl}-4-methoxy-pyrrolidine-2-carboxylic acid 
• 75176-22-6 cis-4-methoxy-L-proline 

Relevant articles and documents

TRIAZINE KINASE INHIBITORS

The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.

VLA-4 INHIBITOR

An object of the present invention is to provide a compound which selectively inhibits binding of a ligand and ±421 integrin (VLA-4), a process for producing the compound, and a medicament containing the compound. A compound represented by the formula (I) etc. orasaltthereof, a process for producing the compound or a salt thereof, a medicament containing the compound or a salt thereof, as well as a preventive and/or a therapeutic agent for a disease caused by cell adhesion, for example, inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and rejection reaction at transplantation, containing the compound or a salt thereof as a primary component. [wherein Y 1 represents a divalent aryl group etc. , V 1 represents an aryl group etc., and R 11 to R 14 represent H, OH or a halogen atom etc.]

Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines

Analogues of captopril, enalaprilat, and the phosphinic acid [[hydroxy(4-phenylbutyl)phosphinyl]acetyl)-L-proline incorporating 4-substituted proline derivatives have been synthesized and evaluated as inhibitors of angiotensin-converting enzyme (ACE) in vitro and in vivo. The 4-substituted prolines, incorporating alkyl, aryl, alkoxy, aryloxy, alkylthio, and arylthio substituents were prepared from derivatives of 4-hydroxy- and 4-ketoproline. In general, analogues of all three classes of inhibitors with hydrophobic substituents on proline were more potent in vitro than the corresponding unsubstituted proline compounds. 4-Substituted analogues of captopril showed greater potency and duration of action than the parent compound as inhibitors of the angiotensin I induced pressor response in normotensive rats. The S-benzoyl derivative of cis-4-(phenylthio)captopril, zofenopril, was found to be one of the most potent compounds of this class and is now being evaluated clinically as an antihypertensive agent. In the phosphinic acid series, the 4-ethylenethioketal and trans-4-cyclohexyl derivatives were found to be the most potent compounds in vitro and in vivo. A prodrug of the latter compound, fosinopril, is also being evaluated in clinical trials.